Cancer Prevention Pharmaceuticals Inc (NASDAQ: CPP) was founded in December 2009. It is a Delaware company headquartered in Tucson, Arizona, USA, with 14 full-time employees (4/15/2016). It is a clinical Biopharmaceutical companies in the stage of development and commercialization are mainly used to treat and prevent certain pre-cancerous, rare diseases and gastrointestinal diseases.
Cancer Prevention Pharmaceuticals (CPP):
Cancer Prevention Pharmaceuticals’ product candidates include:
CPP-1X/sul-used for the treatment of familial adenomatous polyposis (“FAP”), a rare genetic disease that can lead to the growth of thousands of colorectal adenomas (or, adenomatous polyps), modern Medicine believes that this is the main risk factor for colon cancer and is currently in phase III clinical trials; in addition, CPP-1X/sul is still in phase I/II clinical trials for the treatment of neuroblastoma; it is funded by the Juvenile Diabetes Research Foundation Phase I clinical trials for the treatment of early-onset type 1 diabetes; Phase IIa clinical trials for the treatment of gastric cancer funded by NCI; Sponsored research on the treatment of gastric cancer and orphan disease, currently in the preclinical research phase.
Cancer Prevention Pharmaceuticals (CPP) investment:
Cancer Prevention Pharmaceuticals (CPP) submitted its IPO prospectus on 12/23/2015. It was originally planned to be listed on Nasdaq on 2/25/2016, but it is now postponed to the American Stock Exchange (American Stock Exchange) on May 6, 2016. It was listed on the same day as Spring Bank Pharmaceuticals (SBPH), Oncobiologics, Inc. (ONS), Intellia Therapeutics (NTLA), with an issue price of US$12.00-14.00, and 1,923,076 shares issued, raising US$30,961,532.